Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 127 The United Laboratories International Holdings Limited Annual Report 2025 32. SHARE-BASED PAYMENT TRANSACTIONS (Continued) Share award scheme (Continued) Details of movement in the numbers of award shares and the respective weighted average grant date fair value are as follows: Weighted As at Granted Vested Lapsed Cancelled As at average fair 1 January during during during during 31 December value per Grantees Date of grant Vesting period 2025 the year the year the year the year 2025 award shares HK$ Directors Tsoi Hoi Shan 13 November 2023 13 November 2024 to 13 November 2026 383,400 – 191,700 – – 191,700 7.45 Leung Wing Hon 13 November 2023 13 November 2024 to 13 November 2026 267,400 – 133,700 – – 133,700 7.45 Choy Siu Chit 13 November 2023 13 November 2024 to 13 November 2026 179,200 – 89,600 – – 89,600 7.45 Fang Yu Ping 13 November 2023 13 November 2024 to 13 November 2026 124,600 – 62,300 – – 62,300 7.45 Zou Xian Hong 13 November 2023 13 November 2024 to 13 November 2026 124,600 – 62,300 – – 62,300 7.45 Zhu Su Yan 13 November 2023 13 November 2024 to 13 November 2026 124,600 – 62,300 – – 62,300 7.45 Employees 13 November 2023 13 November 2024 to 13 November 2026 6,860,800 – 2,767,900 520,100 142,400 3,430,400 7.45 Total 8,064,600 – 3,369,800 520,100 142,400 4,032,300 7.45